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Polycystic ovarian syndrome (PCOS) is a heterogeneous endocrine disorder associated with 
mitochondrial dysfunction and insulin resistance (IR). MOTS-c, a mitochondrial peptide, 
promotes insulin sensitivity (IS) through activating AKT and AMPK dependent pathways. 
The current study was designed to examine the response of MOTS-c to lipids (intralipid) 
followed by insulin in PCOS and healthy subjects.  
 
METHODS: 
All subjects underwent 5-hour intralipid/saline infusion with a hyperinsulinemic euglycaemic 
clamp in the final 2 hours. Plasma samples were collected to measure circulating MOTS-c 




Intralipid significantly increased plasma MOTS-c both in controls and PCOS subjects, whilst 
the insulin infusion blunted the intralipid induced response seen for both lipids and MOT-c.  
Intralipid elevated plasma MOTS-c to 232±124% of basal in control (P<0.01) and to 
349±206% of basal in PCOS (P<0.001) subjects. Administration of insulin suppressed 
intralipid induced MOTS-c from 232±124% to 165±97% (NS) in control and from 
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intralipid elevated plasma MOTS-c to 305±153% of basal in control (P<0.01) and to 
215±103% of basal in PCOS (P<0.01) subjects; insulin suppressed intralipid induced MOTS-
c only in controls. 
 
CONCLUSIONS:                          
In conclusion, this is the first study to show increased lipid enhanced circulating MOTS-c 
whilst insulin attenuated the MOTS-c response in human. Further, eight weeks of moderate 
exercise training did not show any changes in circulating MOTS-c levels in healthy controls 
and in women with PCOS. 
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Polycystic ovarian syndrome (PCOS) is a complex heterogeneous endocrine disorder 
affecting 5-20% of women in the reproductive age group and is one of the most common 
causes of infertility and metabolic disorder in these women 
1
 . In Qatar, the frequency of 
PCOS among women aged between 18–30 years is estimated to be 12% according to original 
NIH criteria for its diagnosis 
2
. PCOS is a chronic pro-inflammatory state associated with 
obesity, diabetes and dyslipidemia 
1
. Women with PCOS commonly have symptoms of 
oligomenorrhoea, polycystic ovaries, hirsutism, subfertility and insulin resistance (IR) 
3
. 
PCOS women have elevated levels of cardiovascular disease risk (CVD) factors including 
type 2 diabetes (T2DM), carotid intima-media wall thickness and platelet dysfunction 
4
. 
Weight loss improves many clinical features of PCOS, including menses regularity and 
fertility 
5
, and reduces CVD risk factors and IR 
6
. Cellular mechanisms leading to IR in PCOS 
are not clearly understood. Adipose tissue dysfunction and dysregulated expression of 
adipokines have been implicated in the pathophysiology of PCOS. Adipose tissue may 
communicate with the brain, ovaries, and uterus through adipokines, to regulate reproductive 
functions and metabolic features of women with PCOS 
7
. Over-production of pro-
inflammatory adipokines such as TNFα, hyperstimulation of GLUT4 glucose transporter 
8
 




Mitochondrial transcriptome data analysis provided initial evidence for the presence of small 
RNAs and polypeptides originating from mtDNA 
10
 that possess significant biological 
activity 
11, 12
. Humanin was the first mitochondria-derived peptide discovered from the 16s 
ribosomal region of mtDNA 
11
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12s ribosomal region of mtDNA was identified and named MOTS-c (mitochondrial open 
reading frame of the 12S rRNA type-c). As expected, due to its mitochondrial origin, MOTS-
c is expressed in key metabolic organs such as heart, skeletal muscle, testes, liver and brain 
12
. The expression of MOTS-c is down-regulated following calorie restriction in skeletal 
muscle in mice 
12
. Studies in rodents demonstrated that small mitochondrial peptides promote 




MOTS-c enhanced glucose utilization, promoted IS and restored metabolic homeostasis 
through activation of AMPK-dependent mechanisms in skeletal muscle and protected rodents 
against IR induced by obesity and ageing 
12
. Some of the biological responses mediated by 
MOTS-c were due to its ability to upregulate cellular accumulation of 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR), a potent activator of the AMP-activated protein kinase 
(AMPK) pathway and mitochondrial metabolism (24). MOTS-c treatment suppressed bone 
loss following ovariectomy via activation of an AMPK-dependent pathway, suggesting the 
importance of MOTS-c in bone metabolism and osteoporosis 
16
.  
The role of MOTS-c in human pathophysiological conditions such as PCOS that is associated 
with multiple metabolic abnormalities including hyperinsulinemia, IR, obesity, and 
hyperlipidemia, has not been studied previously; therefore the present study was designed to 
examine the functional effects of acute intravenous administration of lipids, insulin and a 
combination of both before and after 8 weeks of a moderate exercise intervention on the 
circulatory levels of MOTS-c in control and PCOS subjects.  
 
Study design and methodology 
 
Study Subjects 
Twelve PCOS women were recruited from the endocrine clinics. PCOS was diagnosed based 
on the presence of two out of three criteria; oligomenorrhoea, clinical or biochemical 
hyperandrogenism and polycystic ovaries on ultrasound after exclusion of other endocrine 
causes of hyperandrogenism  according to the Rotterdam criteria; however, all women with 
PCOS fulfilled all 3 criteria  
17
. Ten healthy volunteers matched for weight and BMI were 
recruited through advertisements at the local University and the hospital intranet. The healthy 
women had regular menstrual cycles and no clinical signs of polycystic ovaries. All the 
participants were nonsmokers, took no regular medications, and had no concurrent illness. 
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preceding the experiments. Subjects with impaired glucose tolerance identified by an oral 
glucose tolerance test at screening were excluded. All women had a pregnancy test prior to 
their inclusion in the study.  Following overnight fasting (O/N) all the subjects underwent 5 
hour saline infusion with IS assessed by a hyperinsulinemic euglycaemic clamp in the final 2 
hours to determine IS (M value).  A week later, the subjects underwent 5 hour 
intralipid/saline infusion (20% soybean oil, 1.2% egg yolk phospholipids, and 2.2% glycerol; 
Kabi Fresenius Pharmacia) with a hyperinsulinemic euglycaemic clamp in the last 2 hours to 
determine IS (M value) 
18
. Following this procedure, all the participants underwent 
supervised moderate intensity (60% maximum oxygen consumption) exercise, 3 hours 
weekly for 8 weeks. During the second phase of this study, the phase 1 protocol was repeated 
in all the subjects. Normal control women had the initial clamp in the first week of their 
menstrual cycle, whilst PCOS women were clamped after 6 weeks amenorrhea. 
 
Insulin clamps 
After fasted blood samples were taken, either normal saline 1.5 mL/min or 20% intralipid 1.5 
mL/min, along with unfractionated heparin sodium 0.3 unit/kg/min was infused for 5 h. At 
180 minutes, a 2 h hyperinsulinemic-euglycemic clamp was started using intravenous soluble 
insulin (Humulin S, Eli Lilly and Co., Indianapolis, IN) at a rate of 80 mU/m2 surface 
area/min for the first 20 minutes, followed by a constant rate of 40 mU/m2 surface 
area/minute for the remaining 100 minutes.  Plasma glucose was clamped at 5.0 mmol/L with 
a variable infusion rate of 20% dextrose, adjusted relative to arterialized blood glucose 
measurements undertaken every 5 minutes.  Endogenous glucose production was more than 
90% suppressed by an acute rise of insulin with the primed insulin infusion.  The rate of 
insulin stimulated glucose disposal (mg/kg/min) (M value),  a measure of IS, was calculated 
from the mean of the five 20 minute periods from 20-120 minutes during the clamp using the 
Defronzo method 
19
. Overall study scheme is shown in Figure 1. 
 
Ethical approval 
The study was approved by the Yorkshire and the Humber Research Ethics Committee 
(reference number 10/H1313/44) and  The Medical Research Center at Hamad Medical 
Corporation (reference number  RP #17261/17) all study participants gave their written 
informed consent before participation. Intralipid and euglycemic clamp studies were 
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Biochemical measurements 
Plasma MOTS-c concentrations were measured using a commercially available ELISA kit 
(Peninsula Laboratories International, Inc, CA 94070 USA) according to manufacturer’s 
recommended protocol, with an intra-assay variation of less than 10%. Serum insulin was 
assayed using a competitive chemiluminescent immunoassay (Euro/DPC, Llanberis, UK). 
Plasma glucose was measured using a Synchon LX 20 analyzer (Bechman-Coulter, High 
Wycombe, UK).  Triglycerides (TG) and total cholesterol were measured by a Synchon LX 
20 analyzer (Beckman-Coulter). The free androgen index (FAI) was calculated by dividing 
the total testosterone by SHBG, and then multiplying by 100. Serum testosterone (nmol/L) 
was assessed by high performance liquid chromatography linked to tandem mass 
spectrometry (Waters Corporation, Manchester, UK), SHBG (nmol/L) levels were measured 
by immunometric assay with fluorescence detection on the DPC Immulite 2000 analyzer 
(Euro/DPC, Llanberis UK). FSH (iu/L) was measured by an Architect analyser (Abbott 
laboratories, Maidenhead, UK); TCH (mmol/L), TG (mmol/L) and HDL (mmol/L) were 
measured using a Synchon LX 20 analyzer (Beckman-Coulter); LDL (mmol/L) was 
calculated using the Friedewald equation. Plasma glucose was measured using a Synchon LX 
20 analyzer (Beckman-Coulter). NEFA was measured using an enzymatic colorimetric 
method (Wako NEFA-H2) on a Konelab20 auto analyzer with a coefficient of variation of 




Power; for 11 subjects with an alpha of 0.05 and power of 80% a difference in means greater 
than 1.26 standard deviations for MOT-c would be required to show significance. Descriptive 
statistics and Means ± Standard Deviations (SD) were calculated for all continuous variables 
in the study. Student t-tests were applied to determine significant differences between the 
groups. Trend analysis in the form of repeated measures ANOVA with post hoc (Bonferroni) 
analysis was performed to evaluate significant differences within the variable. A P value 
<0.05 (two-tailed) was considered for statistical significance. In post hoc analysis comparing 
multiple groups are as follows: a= Baseline to saline comparison; b= Saline to saline+ insulin 
comparison; c = Base line to saline+ insulin comparison. * = P<0.05, ** = P<0.01 and *** = 
P<0.001. Spearman Rank correlation was used to evaluate significant associations between 
variables and MOTS-c. The SPSS 22.0 statistical package used for the study analysis and 
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Results 
Baseline characteristics of control and PCOS subjects                                           
Anthropometric measurements for both PCOS and healthy control subjects are shown in 
Table 1. There was no significant difference in height, weight or BMI between the controls 
and PCOS subjects at the time of recruitment into the study. The mean age [23.4±5.9 in 
controls and 28.8±6.6 in PCOS, (P<0.05)], waist [78.4±11.9 in controls and 91.4±14.9 in 
PCOS, (P<0.05)] and hip size [97.5±13 in controls and 109.8±12.6 in PCOS, (P<0.05)] were 
significantly higher in the PCOS group compared to the healthy volunteers. However, the 
waist to hip ratio was not significantly different between the two groups. 8 weeks of exercise 
did not make any significant alterations to BMI, waist, hip or waist to hip ratio in either the 
healthy or the PCOS subjects (Table 1). 
Basic hormonal measurements such as LH, FSH, estradiol, prolactin, TSH, DHEAS, 
androstenedione, lipid profiles (including TCH, TG, HDL, and LDL), creatinine, creatine 
kinase, platelets, FPG, 2hr PG and HbA1c levels were similar between PCOS and healthy 
subjects. However, blood parameters that are a characteristic feature of PCOS subjects, such 
as the androgen profile, were elevated in PCOS patients as assessed by the FAI [2.05±1.9 in 
controls and 6.12±3.1 in PCOS, (P<0.001)]. The elevated FAI was due to a significant 
decrease in SHBG in the PCOS subjects [70.42±28.9 in controls and 31±20.3 in PCOS, 
(P<0.001)] although total testosterone was not significantly different between the 2 groups 
(Table 1). ALT [16.75±5.1 in controls and 26.25±13.5 in PCOS, (P<0.05)] was elevated in 
PCOS compared to healthy subjects and may reflect fatty liver in the PCOS subjects. 
 
Acute insulin administration does not affect plasma MOTS-c before exercise 
intervention 
In the first phase of the study, we tested the effects of saline and acute insulin administration 
on blood metabolic and biochemical parameters in the study subjects (Table 2). Plasma 
MOTS-c levels were not affected by the saline or insulin infusion in either the PCOS or 
control subjects. Saline infusion did not alter TCH, TG, NEFA and MOTS-c levels either in 
control or PCOS subjects. Administration of insulin infusion along with saline during the last 
two hours of the euglycemic clamp procedure suppressed both TG (b
***
) and NEFA (b
***
) in 
healthy volunteers, but only NEFA (b
***
) was reduced in PCOS subjects. One way ANOVA 
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insulin showed significant changes in TG (P<0.001 in controls vs NS changes in PCOS) and 
NEFA (P<0.001 in controls vs P<0.001 in PCOS subjects). Mean IS index M value was 
significantly higher in controls (4.96 ± 2.0) compared to PCOS subjects (3.26±0.8, P<0.016, 
Table 2). 
 
Acute intralipid infusion increases MOTS-c levels in both control and PCOS subjects 
Intralipid infusion altered many of the blood biochemical parameters except TCH in both 
groups (Table 3). Descriptive statistics assessing the mean differences between each group 
and the overall group comparison showed that the lipid infusion significantly increased 
plasma MOTS-c (a
**
, P<0.05 in controls vs a
**
, P<0.01 in PCOS subjects), and also elevated 
TG (a
***
, P<0.001 in controls vs a
***
, P<0.001 in PCOS subjects) and NEFA (a
***
, P<0.001 in 
controls vs a
***
, P<0.001 in PCOS subjects). To assess the effects of supra-physiological 
insulin whilst maintaining normal plasma glucose at 5mmol/L, insulin was infused along with 
intralipid for 2 hours and the resulting metabolic changes were measured. Insulin suppressed 
lipid-induced MOTS-c more profoundly in PCOS subjects compared to controls (a
*
, P<0.05 
in controls vs a
**
, P<0.01 in PCOS subjects). In addition to the reduction in plasma MOTS-c, 
insulin also suppressed NEFA (b
***
, P<0.001 in controls vs b
***
, P<0.001 in PCOS subjects), 
TG (b
***
, P<0.001 in controls vs NS changes in PCOS subjects), insulin (b
**
, P<0.05 in 
controls vs b
***
, P<0.001 in PCOS subjects) and  the IS index M value was significantly 
reduced both in control (2.4 ± 1.7, P=0.007) and PCOS subjects (1.16 ± 0.8, P<0.0001, Table 
3) in the lipid infusion compared to the saline treatment group as shown in Table 2. 
The percentage changes in plasma MOTS-c following intralipid and insulin before exercise 
intervention is depicted in Figure 1B. Baseline levels were adjusted to 100%.  Intralipid 
elevated plasma MOTS-c from 100% to 232±124% in control subjects and in PCOS subjects 
to 349±206% respectively. Administration of insulin suppressed intralipid-induced MOTS-c 
significantly in both groups, to 165±97% and 183±177% in control and PCOS subjects, 
respectively. Thus, insulin suppressed the lipid-induced increase in MOTS-c levels. 
 
Exercise intervention followed by acute insulin infusion does not affect plasma MOTS-c 
Regular exercise has many beneficial and positive effects in PCOS women. Blood 
biochemical measurements and plasma MOTS-c were measured in response to saline and 
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exercise intervention. Exercise intervention did not show any improvement in the IS index M 
value in either group (Table 4) compared to the sensitivity index M value prior to exercise 
intervention (Table 2).  
Infusion of insulin following saline did not have any significant effects on circulating TG and 
MOTS-c; however, overall group analysis showed significant changes in TCH (P< 0.001) and 
NEFA (P<0.001) in healthy subjects. In PCOS subjects, the effects were more profound after 
exercise intervention compared to controls. In PCOS subjects, insulin infusion suppressed 
circulating NEFA (b
***
, P<0.001) as assessed by post-hoc analysis comparison between each 
group and overall group comparison by ANOVA analysis (Table 4). 
 
Acute intralipid infusion enhances, and insulin suppresses, intralipid-induced plasma 
MOTS-c following exercise intervention                        
In the second phase of the study, we compared the effects of lipid and the lipid + insulin 
combination on plasma MOTS-c and other blood parameters following 8 weeks of supervised 
exercise reaching VO2 max of 60% in each of the participating subjects. We observed a small 
but insignificant increase in baseline plasma MOTS-c in both healthy and PCOS subjects 
following exercise.  
The overall group ANOVA analysis revealed the effect of intralipid and intralipid + insulin 
insults following exercise on blood biochemical parameters, such as TCH, TG and NEFA, 
were similar to that found prior to exercise training in healthy subjects. The net change in 
plasma MOTS-c in the lipid and the intralipid + insulin treatment group was significantly 
elevated following exercise in healthy subjects (P<0.01) compared to (P<0.05) before 
exercise measurements in the same subjects (Table 3 compared to Table 5). However, this 
differed to what was found in the PCOS subjects where the combination of intralipid + 
insulin administration lowered MOTS-c (P< 0.05, Table 5) after exercise compared to 
observed changes (P<0.01, Table 3) in MOTS-c with the lipid and the lipid + insulin insult 
prior to the exercise intervention. The percentage changes in plasma MOTS-c following 
intralipid and insulin after exercise intervention in PCOS and control subjects is depicted in 
Figure 1 D. Baseline levels were adjusted to 100%. Intralipid elevated plasma MOTS-c from 
100% to 305 ± 153% in control subjects and to 215 ± 103% in PCOS subjects. 
Administration of insulin suppressed intralipid-induced MOTS-c significantly in both groups 
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Correlation of MOTS-c with covariates                                                    
In all participants (n =10 controls and n=12 PCOS subjects), Spearman Rank analysis showed 
that, prior to exercise, plasma MOTS-c negatively correlated with plasma glucose (PG) at 
baseline (0 min) only in the PCOS group (r = - 0.773; P = 0.01). Following intralipid + 
insulin administration following the lipid only infusion, MOTS-c showed a significant 
positive correlation with NEFA (r = 0.773; P = 0.005) in controls and negatively correlated 
to TCH in PCOS subjects (r = -.580; P = 0.048). In the same subjects following 8 weeks of 
endurance exercise, plasma MOTS-c showed no significant correlation in controls whilst a 
negative correlation was observed in the PCOS group (r = -0 .733; P = 0.013) at 0 min. 
Following intralipid administration, plasma MOTS-c positively correlated with TG (r = 
.745; P = 0.013) and NEFA (r = .758; P = 0.011) in controls but no significant correlation 
was observed in PCOS subjects. However, in the combination intralipid + insulin 
administration samples, MOTS-c showed a positive correlation with TG (r = .648; P = 0.043) 
and NEFA (r = .855; P = 0.002) in controls though no significant correlation was observed in 
PCOS subjects (Supplementary table S1). 
 
Discussion 
In this study the role of FFA in the regulation of MOTS-c was evaluated and showed that 
MOTS-c was increased in both PCOS and controls by the intralipid infusion, but that the 
MOTS-c levels did not fall following the infusion of insulin that reduced NEFA and TG 
levels. The hyperinsulinemic-euglycemic clamp technique is a well-accepted model for 
studying in vivo IR, skeletal muscle IS and glucose metabolism in human subjects 
19
. Whilst 
there are studies in vitro and in animal models, human studies are scant and this is the first to 
report the response of MOTS-c in such an interventional study. 
Intralipid administration elevates circulating FFA levels that have deleterious effects in 
humans 
20
, promotes proinflammatory cytokine TNFα secretion, interferes with glucose 
metabolism, obstructs glucose oxidation and reduces glucose disposal rate 
21, 22
. As a 
consequence, this promotes hepatic and peripheral IR 
23, 24
. More than 50% of women with 
PCOS have lower IS and higher IR 
6
 compared to healthy women. The metabolic pathways 
responsible for this contrasting IR profile are not completely understood. PCOS women who 
lead a sedentary lifestyle and consume high caloric diets develop higher insulin resistance 
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We hypothesized that intralipid and insulin may differentially regulate IR, resulting in altered 
metabolic processes and altered glucose metabolism that may influence plasma MOTS-c 
expression. Further, increasing plasma FFA concentrations through an intralipid infusion 
increases IR 
25
 in healthy subjects and aggravates preexisting IR in PCOS subjects. This 
study was designed to compare the effects of FFA elevation through intralipid infusion and 
the influence of insulin infusion on fasting and insulin-stimulated glucose metabolism and to 
understand the importance of this metabolic shift on circulating MOTS-c in PCOS and 
healthy women. In accord with previous reports 
26, 27
, acute insulin administration 
significantly suppressed NEFA both in control and PCOS subjects, but with no alteration in 
plasma MOTS-c in either group, suggesting that acute insulin administration does not affect 
circulating MOTS-c. However, one cannot rule out the possibility of alterations in MOTS-c 
following chronic insulin administration since this was not tested as part of our study 
protocol.  
Acute intralipid infusion diminished whole-body IS and elevated FFAs, changes 
accompanied by a parallel rise in plasma TG and an increase in circulating MOTS-c in both 
groups. The elevated FFAs and MOTS-c levels were suppressed upon insulin administration 
during the final 2 hours of the clamp procedure. The pioneer study on MOTS-c suggested that 
MOTS-c may be released into the circulation by key metabolic organs, such as the brain, 
skeletal muscle, heart and testes, comprising the major sources of the circulating pool of 
MOTS-c 
12
. This study did not address the source of the circulating MOTS-c levels; however, 
given MOTS-c is a mitochondrial ribosomal protein, one would assume that the majority of 
the recognized cell types could produce MOTS-c and contribute to the circulating pool. 
Regular moderate exercise reduces diabetes risk by more than 50% in subjects at risk of 
developing diabetes 
28
. For individuals with diabetes, exercise makes it easier to control 
blood glucose via a reduction in skeletal muscle IR and an improvement in IS, leading to a 
reduction in long-term diabetes related comorbidities 
29
. Obese PCOS women have an 
increased risk of metabolic syndrome with elevated cardiovascular risk factors 
30
. Lifestyle 
modification and weight reduction enhances sex hormone binding globulin (SHBG) levels, 
reduces testosterone, restores ovulation and improves pregnancy rates 
31
. Increased physical 
activity and weight loss improves the biochemical and phenotypic features of PCOS, thus 
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Endurance exercise intervention did not reduce weight or alter plasma MOTS-c significantly 
in either group; however, enhanced glucose utilization, through an improvement in IS 
35
, and 
a reduction in IR with lower plasma glucose levels were seen following the hyperinsulimic 
euglycemic clamp in PCOS subjects (Table 2 and Table 4). Increasing physical activity is a 
therapeutic option for reducing abnormalities associated with metabolic syndrome 
36
. Some 
of the beneficial effects of exercise could be attributed to alterations in the adipokine profile, 
as exercise lowers proinflammatory cytokines that are responsible for the chronic 
inflammatory state and increased IR, whilst levels of anti-inflammatory cytokines are 
increased in the circulation and have been implicated in reducing IR 
37
. In our study, a small 
but insignificant elevation in plasma MOTS-c levels was observed following exercise in both 
the PCOS and the healthy groups of women. This would also suggest that the changes in IR 
seen following exercise do not have a direct effect on MOTS-c, but rather MOTS-c may 
reflect FFA changes. 
Lee et al. showed that MOTS-c treated mice subjected to hyperinsulinemic-euglycemic 
clamps required more infused glucose and had a better insulin-stimulated glucose disposal 
rate compared to controls, suggesting an improvement in IS. MOTS-c levels in the circulation 
and in skeletal muscle decline following induction of IR in mice, and IR was reversed by 
MOTS-c administration showing improved insulin signaling in skeletal muscle and IS 
12
. In 
this context, the small rise in circulating MOTS-c observed in our study following exercise 
may be physiologically beneficial in humans. It is difficult to explain the importance of our 
finding, given that our sample size is small and that there are no similar human studies 
available with which to compare our results. However, in rodents, MOTS-c treatment 
promotes energy expenditure through activation of AMPK pathways and enhances insulin 
signaling through activation of the AKT signaling pathway, thus promoting IS in skeletal 
muscle 
12
.  Intralipid infusion prior and following endurance exercise significantly increased 
circulating TG and NEFA levels and this was accompanied by a parallel rise in plasma 
MOTS-c, suggesting that circulating MOTS-c is regulated by lipids in vivo. Administration of 
the insulin infusion during the last 2 hours of intralipid administration suppressed intralipid, 
induced an elevation in NEFA and also reduced plasma MOTS-c. In a recent study in 
ovariectomy induced obese mice MOTS-c treatment decreased circulating free fatty acids, 
lowered hepatic triglyceride content, down regulated the genes involved in lipogenesis and 
prevented ovariectomy induced weight gain 
38
. From the above study in mice it could be 
speculated that the rise in plasma MOTS-c observed following intralipid administration could 










This article is protected by copyright. All rights reserved. 
effects caused by the rise in NEFA and triglycerides. Furthermore, the changes in IR 
associated with MOTS-c may be indirectly due to alterations in FFA levels. 
The main strengths of this study are this is the first in vivo study to show the relationship 
between circulating lipids and MOTS-c in humans and that gold standard methodology for 
this intensive interventional study and well-supervised exercise intervention were employed. 
However, the limitations were that this was a small group of women with PCOS, though all 
fulfilled all three of the diagnostic criteria for its diagnosis thereby reducing heterogeneity; 
however, the groups were not well matched for BMI and age. For the reduction of MOT-c 
following insulin during the lipid infusion that did not differ in the control subjects the study 
was underpowered to determine the significance of this finding that could represent a type 2 
statistical error, given that the reduction of MOT-c in the PCOS group was significant. The 
diagnostic criteria used to define the PCOS group would likely not have altered the results 
here, as IS was reported to be no different between the original NIH criteria and Rotterdam 
criteria 
39
. In addition, the findings may not be generalized to other populations; however, due 
to the intense nature of the study protocol requiring multiple visits, and the frequent blood 
sampling needed to stabilize plasma glucose at steady state levels during clamp conditions, it 
is not feasible to perform such studies in a large cohort of subjects 
19
.  For this reason, the 
results must be interpreted cautiously and thus further studies in large cohorts of subjects are 
warranted to confirm our findings. 
In conclusion, this is the first study to show lipid increases circulating MOTS-c and insulin 
attenuates lipid induced MOTS-c in humans. Further eight weeks of moderate exercise 
training did not show any changes in circulating MOTS-c levels in healthy controls and in 
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PCOS = Type 2 diabetes 
IR = insulin resistance 
IS = Insulin sensitivity 
MOTS-c = mitochondrial open reading frame of the 12S rRNA type-c 
BMI= body mass index 
SBP = systolic blood pressure 
DBP = diastolic blood pressure 
TCH = total cholesterol 
HDL = high density lipoprotein 
LDL = low density lipoprotein 
TG = triglycerides 
HbA1c = glycated hemoglobin 
ALT = alanine aminotransferase 
TCH = total cholesterol 
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Figure and table legends 
 
 
Figure 1: Effect of acute administration of intra lipid and insulin on plasma MOTS-c before 
and after exercise in control and PCOS subjects. A) Saline and insulin before exercise; B) 
Intralipid and Insulin before exercise; C) Saline and insulin after exercise; D) Intralipid and 
insulin after exercise. ***-p<0.0001; **-p<0.001; *- p<0.05. 
 
Table 1: Anthropometric, biochemical and hormonal measurement of study subjects. . 
Wt - weight; bf- before; af- after; BMI- Body mass index; ex- exercise; WHR- Waist to hip 
ratio; NS-not significant. FAI-Free androgen index; SHBG-Sex hormone-binding globulin; 
LH-Luteinizing hormone; FSH-Follicle stimulating hormone; TCH-Total cholesterol; TG; 
Triglycerides; HDL-High density lipoprotein; LDL-Low density lipoprotein; CK-Creatine 
kinase; ALT-Alanine transaminase; FPG-Fasting plasma glucose; PG-Plasma glucose; 
HbA1c-hemoglobin A1c; TSH-Thyroid stimulating hormone; DHEAS-
Dehydroepiandrosterone; NA-not significant. 
  
Table 2:  Effects of acute insulin administration on blood TCH, TG, NEFA, M-value 
and MOTS-c levels in study subjects before exercise intervention. a= Baseline to saline 
comparision; b= Saline to saline+ insulin comparision; c = Base line to saline+ insulin 
comparision. TCH-Total cholesterol; M-value – Insulin sensitivity index; TG; Triglycerides; 
NEFA- non-esterified fatty acid; MOTS-c- mitochondrial open reading frame of the 12S 
rRNA-c; NA-not significant. 
 
Table 3:  Effects of acute intralipid and insulin administration on blood TCH, 
triglycerides, NEFA, M-value and MOTS-c levels in study subjects before exercise 
intervention. a= Baseline to lipid comparision; b= Lipid to Lipid+ insulin comparision; c = 
Base line to lipid+ insulin comparision. TCH-Total cholesterol; M-value – Insulin sensitivity 
index; TG; Triglycerides; NEFA- non-esterified fatty acid; MOTS-c- mitochondrial open 
reading frame of the 12S rRNA-c; NA-not significant. 
 
Table 4:  Effects of acute insulin administration on blood TCH,  NEFA, M-value and 
MOTS-c levels in study subjects after exercise intervention. a= Baseline to saline 
comparision; b= Saline to saline+ insulin comparision; c = Base line to saline+ insulin 
comparision. TCH-Total cholesterol; M-value – Insulin sensitivity index; TG; Triglycerides; 
NEFA- non-esterified fatty acid; MOTS-c- mitochondrial open reading frame of the 12S 
rRNA-c; NA-not significant. 
 
Table 5: Effects of acute intralipid and insulin administration on blood TCH,  TG, 
NEFA, M-value and MOTS-c levels in study subjects after exercise intervention. a= 
Baseline to lipid comparison; b= lipid to lipid + insulin comparison; c = Baseline to lipid + 
insulin comparision. TCH-Total cholesterol; M-value – Insulin sensitivity index; TG; 
Triglycerides; NEFA- non-esterified fatty acid; MOTS-c- mitochondrial open reading frame 
of the 12S rRNA-c; NA-not significant. 
 
Supplementary table S1:  Spearman Rank correlation of MOTS-c with variables. TCH-
Total cholesterol; TG; Triglycerides; PG-Plasma glucose; NEFA- non-esterified fatty acid; 
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  Anthropometric measurements Control (n=10) PCOS (n=12)   
  Mean ± SD Mean ± SD Significance 
Age (y) 23.4±5.9 28.8±6.6 p<0.05 
Height (m) 1.7±0.03 1.7±0.1 NS 
Wt-bf-ex (kg) 69.7±15.5 82.9±17.1 NS 
Wt-af-ex (kg) 70.6±16.2 85.0±19.6 NS 
BMI-bf-ex (kg/  m2 )  25.1±5.2 29.3±6 NS 
BMI-af-ex  (kg/  m2 ) 25.4±5.4 30.6±6.3 NS 
Waist-bf-ex  (cm) 78.4±11.9 91.4±14.9 p<0.05 
Waist-af-ex  (cm) 76.8±13.2 91.6±15.7 p<0.05 
Hip-bf-ex (cm) 97.5±13 109.8±12.6 p<0.05 
Hip-af-ex (cm) 99.9±13.3 111.6±12.8 NS 
WHR-bf-ex (cm) 0.8±0.1 0.8±0.1 NS 
WHR-af-ex (cm) 0.8±0.1 0.8±0.1 NS 
    
Baseline blood biochemistry and 
hormonal measurements 
   
FAI 2.05±1.9 6.12±3.1 p<0.001 
Testosterone (nmol/L) 1.08±0.3 1.48±0.8 NS 
SHBG (nmol/L) 70.42±28.9 31±20.3 p<0.001 
LH (iu/L) 6.97±11.5 5.123±3.8 NS 
FSH (iu/L) 4.9±1.8 6.72±10.2 NS 
Oestradiol (pmol/L) 168.50±195.1 178.23±129 NS 
TCH (mmol/L) 4.6±0.9 4.15±0.6 NS 
TG (mmol/L) 0.91±0.4 1.08±0.5 NS 
HDL (mmol/L) 1.5±0.4 1.25±0.4 NS 
Table 1: Anthropometric, biochemical and hormonal measurement of study subjects 
 














































LDL (mmol/L) 2.63±0.6 2.37±0.5 NS 
TCH/HDL ratio 3.19±0.8 3.44±0.9 NS 
Creatine  (nmol/L) 63.83±7.5 64.77±10.9 NS 
CK (U/L) 72.73±27 90.25±33.05 NS 
ALT (U/L) 16.75±5.1 26.25±13.5 p<0.05 
Platelets  x10^9/L 267±72.08 285.67±49.2 NS 
 FPG (nmol/L) 4.72±0.5 4.74±0.4 NS 
2 hrPG (nmol/L) 4.69±1.9 5.56±1.7 NS 
HbA1c (mmol/mol) 32.8±5.8 33.36±2.7 NS 
Prolactin  (mU/L) 436±230.3 324.23±112 NS 
TSH  (mU/L) 2.15±1.6 1.6±0.6 NS 
DHEAS (umol/l) 8±2.6 5.46±3.53 NS 
Androstenedione (nmol/L) 9.94±3.7 10.66±5.3 NS 















                     








analysis PCOS (N=12) ANOVA 
Post-Hoc 
analysis 
Biochemistry Infusion  Mean ± SD Significance Significance Mean ± SD Significance Significance 
TCH (mmol/L) 





































  NS 




M-value  4.96± 2.0   3.26± 0.8   
                            
 




















                     
  
Table 3:  Effects of acute intralipid and insulin administration on blood TC, TG, NEFA, MOTS-c levels and M-Value  in study subjects  
before exercise intervention. 
 
  
Control (N=10) ANOVA 
Post-Hoc 
analysis PCOS (N=12) ANOVA 
Post-Hoc 
analysis 
Biochemistry Infusion  Mean ± SD Significance Significance Mean ± SD Significance Significance 
TCH (mmol/L) 




Lipid 3.95±0.8 3.61±0.6 
Lipid + 
Ins 4.19±0.7 3.65±0.6 
NEFA 
(µmol/L) 




Lipid 3122.25±1023.5 3569.91±1147 
Lipid + 
Ins 1427.63±727.7 1784.77±869.2 
TG (mmol/L) 
Base line  0.88±0.3 
P<0.001 a***, c*** 
0.96±0.5 
P<0.001 a***, c*** 
Lipid 4.94±2.4 5.55±3.05 
Lipid + 
Ins 5.2±2.2 6.17±3.6 
MOTS-c 
(pg/ml) 










  a**,b*,c* 
Lipid 927.89±638.9 1139.38±618.9 
Lipid + 
Ins 793.10±811.3 626.37±260.7 
M-value  2.44± 1.7   1.16± 0.8   
                    a= Baseline to lipid comparison; b= Lipid to Lipid+ insulin comparison; c = Base line to lipid+ insulin comparison.          
            
 
                    
 
 
















































































































        
M-value  5.5± 1.9   3.92± 1.5   
                        a= Baseline to saline comparison; b= Saline to saline+ insulin comparison; c = Base line to saline+ insulin comparison 




















































Lipid 4.23±0.6 3.51±0.6 


















Lipid 4.07±1.4 4.9±2.4 


















Lipid 3106±976 2989±905 


















Lipid 1006± 610 960±504 
Lipid + Ins 698±503 800±301 
        
M-value  3.01± 1.4   1.53± 0.8   
                      
        a= Baseline to lipid comparison; b= lipid to lipid + insulin comparison; c= Baseline to lipid + insulin comparison. 
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